The U.S. Food and Drug Administration (FDA)'s approval of artificial intelligence (AI) tools has raised doubts among doctors about their ability to improve patient care.
American Medical Association president Jesse Ehrenfeld said, "If physicians are going to incorporate these things into their workflow, if they're going to pay for them, and if they're going to use them—we're going to have to have some confidence that these tools work."
The trial of Google's Med-PaLM 2 chatbot for healthcare workers has provoked issues about patient privacy and informed consent, and the FDA's oversight of large language models is trailing AI's rapid evolution.
The agency also has no influence over the development of AI tools built by health systems for internal use, although doctors are hesitant to deploy them due to the dearth of publicly available information.
The FDA's Jeffrey Shuren suggested establishing AI-testing laboratories, which would require amending federal law.
From The New York Times
View Full Article - May Require Paid Subscription
Abstracts Copyright © 2023 SmithBucklin, Washington, D.C., USA
No entries found